Pathology of IPF

Oct 1, 2016 by in RESPIRATORY Comments Off on Pathology of IPF

Fig. 7.1 Histology of UIP. (a) Panoramic view. Patchy involvement and perilobular dense fibrosis with structural remodeling. Bar: 1 cm. Hematoxylin-eosin staining (HE). (b, c) Fibroblastic focus on dense fibrosis (arrow)….

read more

Common Pathways in IPF and Lung Cancer

Oct 1, 2016 by in RESPIRATORY Comments Off on Common Pathways in IPF and Lung Cancer

MicroRNA Tumorigenesis IPF development Related molecules miR-21 ↑ ↑ TPM1, PDCD4, PTEN,TGFβ, NFIB, mapsin, Spry-2, MARCKS MMPs, RECK, SMAD2, SMAD7, FGF2 Let-7 ↓ ↓ TGFβ, HMGA2, SMAD3, RAS, CDC25A miR-155…

read more

Pharmacotherapy of IPF (Corticosteroids, Immunosuppressants, Etc.)

Oct 1, 2016 by in RESPIRATORY Comments Off on Pharmacotherapy of IPF (Corticosteroids, Immunosuppressants, Etc.)

Treatment Recommended Strength of recommendation Quality of evidence Pharmacologic therapies Corticosteroid monotherapy No Strong ⊕○○○ Colchicine No Strong ⊕○○○ Cyclosporine A No Strong ⊕○○○ Corticosteroid + immunomodulatory No Strong ⊕○○○ Corticosteroid + azathioprine + acetylcysteine Majority…

read more

Non-pharmacological Therapy for IPF

Oct 1, 2016 by in RESPIRATORY Comments Off on Non-pharmacological Therapy for IPF

Fig. 11.1 Oxygen time courses in pulmonary capillary when diffusion is normal and abnormal (e.g., because of thickening of the blood–gas barrier by disease) (Reprinted with permission of Wolters Kluwer…

read more

Specific Serum Markers of IPF

Oct 1, 2016 by in RESPIRATORY Comments Off on Specific Serum Markers of IPF

Fig. 5.1 Structures of SP-A and SP-D. Monomeric and oligomeric structures of SP-A and SP-D. Monomeric structures can be conceptually divided into four major structural domains: a short N-terminal segment…

read more

Acute Exacerbation of IPF

Oct 1, 2016 by in RESPIRATORY Comments Off on Acute Exacerbation of IPF

Fig. 3.1 Clinical disease courses in patients with IPF. The typical natural history of IPF is the slow progression of the disease with a median survival period of approximately 3 years…

read more

Pharmacotherapy of Acute Exacerbation of IPF (Corticosteroids, Immunosuppressants, and Direct Hemoperfusion with Polymyxin)

Oct 1, 2016 by in RESPIRATORY Comments Off on Pharmacotherapy of Acute Exacerbation of IPF (Corticosteroids, Immunosuppressants, and Direct Hemoperfusion with Polymyxin)

© Springer Japan 2016Hiroyuki Nakamura and Kazutetsu Aoshiba (eds.)Idiopathic Pulmonary Fibrosis10.1007/978-4-431-55582-7_12 12. Pharmacotherapy of Acute Exacerbation of IPF (Corticosteroids, Immunosuppressants, and Direct Hemoperfusion with Polymyxin) Are High-Dose Steroid Therapy, Other Immunosuppressant Therapy, and PMX Therapy…

read more
Get Clinical Tree app for offline access